Executive Summary
Marinus Pharmaceuticals seeks to invalidate Ovid Therapeutics’ 2022 ganaxolone patent covering methods for treating status epilepticus, arguing anticipation, obviousness, and lack of enablement based on prior publications and press releases.
Related Cases
Apple Inc.vsApex Beam Technologies LLC
Apple and Apex Beam settled their dispute over U.S. Patent 10,912,081 and jointly moved to terminate the inter partes review.
Samsung Electronics Co., Ltd. et al.vsGenghisComm Holdings, LLC
Samsung has filed an IPR petition challenging 18 claims of GenghisComm’s ’508 patent, asserting anticipation and obviousness over Shattil-537 and secondary references Doufexi and Lucent. The petition argues strong merits and cites Fintiv factors to oppose discretionary denial.
United Therapeutics CorporationvsActelion Pharmaceuticals Ltd. et al.
The PTAB denied institution for IPR2025-01139, preventing United Therapeutics Corporation from challenging Actelion's patent 8268847.
JPMorgan Chase Bank, N.A.vsIdentitii Limited
JPMorgan Chase Bank challenges Identitii Limited's patent (10984413) on grounds of obviousness and lack of written description/enablement. The Petitioner argues the claims are predictable combinations of prior art references, specifically Kennedy and Kurani-816.
Google LLCvs--
Google LLC's attempt to challenge a patent via IPR was denied by the PTAB because another, earlier petition challenging the same patent had already been instituted.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.